AbbVie

3Q Revenues: $5.0 billion (+8%)

3Q Earnings: $506 million (-48%)

YTD Revenues: $14.5 billion (+6%)

YTD Earnings: $2.6 billion (-14%)

Comments: HUMIRA sales increased 18% to $3.3 billion in the quarter. Kaletra sales were $256 million, up 8%. Synthroid sales were up 24% to $200 million. Creon sales were up 48% to $148 million. Synagis sales were up 12% to $109 million and Duodopa sales were $56 million, up 20%. AndroGel sales were down 7% to $232 million. Dyslipidemia sales were down 77% to $56 million due to loss of exclusivity. On Oct. 20, AbbVie and Shire terminated their proposed merger following AbbVie’s decision to withdraw support for the proposed transaction based on its assessment of a notice issued by the the U.S. Department of Treasury that included changes that negatively impacted the economics of the transaction.